Detalles de la búsqueda
1.
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Breast Cancer Res
; 21(1): 39, 2019 03 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30867034
2.
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
BMC Cancer
; 18(1): 965, 2018 Oct 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30305055
3.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 18(12): 1688-1700, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29146401
4.
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 17(3): 367-377, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26874901
5.
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
Eur J Cancer
; 184: 48-59, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36898233
6.
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.
Breast Cancer Res Treat
; 134(1): 333-43, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22538770
7.
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Clin Cancer Res
; 27(3): 807-818, 2021 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33122343
8.
Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients.
Anticancer Res
; 28(3B): 1733-40, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18630452
9.
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
J Clin Oncol
; 23(4): 792-9, 2005 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15681523
10.
The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial.
J Clin Oncol
; 22(12): 2294-302, 2004 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15197190
11.
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
Clin Cancer Res
; 8(5): 1073-9, 2002 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-12006521
12.
Filgrastim-mediated neutrophil recovery in patients with breast cancer treated with docetaxel and doxorubicin.
Pharmacotherapy
; 23(11): 1424-31, 2003 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-14620389
13.
A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer.
Oncol Rep
; 10(3): 715-24, 2003.
Artículo
en Inglés
| MEDLINE | ID: mdl-12684649
14.
Cell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: a validation study on US Oncology 02-103 clinical trial.
BMC Med Genomics
; 5: 51, 2012 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-23158478
15.
Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.
J Natl Cancer Inst
; 103(3): 264-72, 2011 Feb 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-21191116
16.
A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer.
Cancer
; 116(4): 814-21, 2010 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20052721
17.
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.
Lancet Oncol
; 8(3): 203-11, 2007 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-17329190
18.
Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.
Breast J
; 8(1): 2-9, 2002.
Artículo
en Inglés
| MEDLINE | ID: mdl-11856154
Resultados
1 -
18
de 18
1
Próxima >
>>